Share Prices & Company Research

Market News

12 Jul 2019 | 08:54

Open Orphan sells remaining shares in Integumen

Orpha drug consultancy Open Orphan said it had sold its remaining shareholding in skin treatment focused Integumen.

Total proceeds of the sale were around £567k.

'The disposal allows the company to focus all its resources on its core strategy of creating a focused orphan drug platform offering a wide range of complementary services to the developers of rare and orphaned drugs,' it said.

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.